Fig. 1
(A) Framework for defining a strategic methodology to develop the PBPK model and attain results. IV intravenous, CKD chronic kidney disease, LC liver cirrhosis, MW molecular weight, pKa acid dissociation constant, CLR renal clearance, CLH hepatic clearance, PK pharmacokinetic, PBPK model physiologically based pharmacokinetic model. (B) Whole body physiologically based pharmacokinetic model in PK-Sim software, QH, QHA, QPV, QIC, QOC are blood flows in hepatic vein, hepatic artery, hepatic portal vein, blood flows into and out of other compartments, EG and EH represent fractions undergoing first pass metabolism in GIT and liver.
